Precision Nanomedicine (Jan 2019)
The potential utility of iron oxide nanoparticles for the treatment of skin inflammation in a mouse model of psoriasis
Abstract
Several studies have demonstrated that immunosuppressive effects accompany systemic administration of some iron oxide nanoparticles (IONPs). In our earlier study, conducted using human peripheral blood mononuclear cells, we showed that therapeutic formulation of IONPs, Feraheme, approved for clinical use in the US for the treatment of iron deficiency in chronic kidney disease, suppresses the function of activated T-cells in vitro via a mechanism involving mitochondrial damage. Here we report an in vivo study demonstrating that topical application of Feraheme inhibits the development of skin lesions in the mouse model of chemically induced psoriasis. [READ ARTICLE](https://precisionnanomedicine.com/article/7362)